Skip to main content

Table 2 Subgroup analysis of the biochemical cure rate in patients treated with DAs and surgery treatment

From: Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis

  DAs Surgery
Pooled result Number of studies Number of patients Pooled result Number of studies Number of patients
Total 0.78 (0.75, 0.82) 74 2659 0.66 (0.62, 0.71) 81 4397
Microprolactinoma 0.86 (0.78, 0.94) 9 238 0.79 (0.72, 0.85) 23 686
Macroprolactinoma 0.77 (0.72, 0.83) 27 1228 0.57 (0.46, 0.68) 15 666
Giant prolactinoma 0.62 (0.51, 0.74) 8 176 0.35 (0.08, 0.62) 3 55
1980–1989 0.74 (0.59, 0.89) 6 106 0.63 (0.52, 0.73) 15 1134
1990–1999 0.83 (0.75, 0.90) 11 397 0.64 (0.46, 0.83) 7 262
2000–2009 0.79 (0.72, 0.86) 18 605 0.69(0.60, 0.78) 20 947
2010–2019 0.77 (0.71, 0.82) 39 1551 0.67 (0.60, 0.74) 39 2054
Bromocriptine 0.70 (0.60, 0.80) 14 330 NA NA NA
Cabergoline 0.83 (0.78, 0.87) 32 1368 NA NA NA
Microscopic surgery NA NA NA 0.68 (0.56, 0.80) 14 1043
Endoscopic surgery NA NA NA 0.72 (0.65, 0.79) 29 1156
  1. Das dopamine agonists, NA not applicable, because the data was not discussed or calculated in the meta-analysis